| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| (+)-JQ1; (+)-JQ1 | CFN60008 | 1268524-70-4 | C23H25ClN4O2S = 456.99 | 5mg | QQ客服：2056216494 |
| 罗米地辛; Romidepsin | CFN60009 | 128517-07-7 | C24H36N4O6S2 = 540.7 | 5mg | QQ客服：2159513211 |
| 吡唑蒽酮(SP600125); Pyrazolanthrone (SP600125) | CFN60010 | 129-56-6 | C14H8N2O = 220.23 | 5mg | QQ客服：1457312923 |
| Y-27632 2HCl; Y-27632 2HCl | CFN60011 | 129830-38-2 | C14H21N3O.2HCl = 320.26 | 5mg | QQ客服：2159513211 |
| 伏立诺他; Vorinostat(SAHA) | CFN60012 | 149647-78-9 | C14H20N2O3 = 264.3 | 5mg | QQ客服：215959384 |
| 4-(4-氟苯基)-2-(4-甲基亚磺酰基苯基)-5-(4-吡啶基)-1H-咪唑; SB203580 | CFN60013 | 152121-47-6 | C21H16FN3OS = 377.43 | 5mg | QQ客服：2056216494 |
| 伊马替尼; Imatinib (STI571) | CFN60014 | 152459-95-5 | C29H31N7O = 493.6 | 5mg | QQ客服：2056216494 |
| LY294002; LY294002 | CFN60015 | 154447-36-6 | C19H17NO3 = 307.34 | 5mg | QQ客服：1413575084 |
| Perifosine (KRX-0401); Perifosine (KRX-0401) | CFN60016 | 157716-52-4 | C25H52NO4P = 461.66 | 5mg | QQ客服：3257982914 |
| 依维莫司; Everolimus (RAD001) | CFN60017 | 159351-69-6 | C53H83NO14 = 958.22 | 5mg | QQ客服：215959384 |
| 2-(2-氨基-3-甲氧基苯基)-4H-1-苯并吡喃-4-酮; PD98059 | CFN60018 | 167869-21-8 | C16H13NO3 = 267.28 | 5mg | QQ客服：1413575084 |
| 硼替佐米; Bortezomib (PS-341) | CFN60019 | 179324-69-7 | C19H25BN4O4 = 384.2 | 5mg | QQ客服：2159513211 |
| Z-VAD-FMK; Z-VAD-FMK | CFN60020 | 187389-52-2 | C22H30FN3O7 = 467.49 | 5mg | QQ客服：2056216494 |
| BAY 11-7082; BAY 11-7082 | CFN60021 | 19542-67-7 | C10H9NO2S = 207.25 | 5mg | QQ客服：215959384 |
| 渥曼青霉素; Wortmannin | CFN60022 | 19545-26-7 | C23H24O8 = 428.43 | 5mg | QQ客服：2056216494 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)